Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

Blueprint for selectivity

Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP

October 25, 2018 10:55 PM UTC

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in development.

Blueprint is betting high selectivity and precision targeting will give its IND-ready BLU-782 a better benefit-risk profile than others in the field. It plans to test the compound in healthy volunteers in 1Q19...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article